JRSSOTCServices-HospitalsFiscal year ends December 31
JRSIS HEALTH CARE Corp
Financials through Q3 FY2024, quarter ended Sep 30, 2024Last filing: 10-Q on Dec 20, 2024
$0.01+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $1.10M
- P/E (TTM)
- –
- Dividend yield
- –
JRSIS HEALTH CARE Corp revenue by segment
By business segment
By product or service
| Revenue | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Patient services [Member] | $26.31M | $20.69M | $17.22M | $13.26M | 73.7% | +27.2% |
| Patient services [Member] | $26.31M | $20.69M | $17.22M | $13.26M | 73.7% | +27.2% |
| Medical consulting [Member] | $12.62M | $9.64M | – | – | 35.3% | +31.0% |
| Medical treatment [Member] | $12.29M | $9.94M | – | – | 34.4% | +23.6% |
| Medicine [Member] | $9.40M | $10.78M | – | – | 26.3% | -12.8% |
| Western pharmaceuticals [Member] | $7.24M | $8.33M | – | – | 20.3% | -13.1% |
| Others [Member] | $1.40M | $1.11M | – | – | 3.9% | +26.4% |
| Herbal medicine [Member] | $1.30M | $1.05M | – | – | 3.6% | +23.6% |
| Chinese medicine [Member] | $864.53K | $1.40M | – | – | 2.4% | -38.2% |
| Pharmaceuticals [Member] | – | $10.78M | $11.18M | $10.89M | – | – |
| Medicine | – | $10.78M | $11.18M | $10.89M | – | – |
By region
From the segment and revenue-disaggregation notes of Jrsis Health Care's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.